Statin use in primary inflammatory breast cancer: a cohort study
Statin use in primary inflammatory breast cancer: a cohort study
复制标题
DOI：
10.1038/bjc.2013.342
复制
发表时间：
2013-07-23
影响因子：
8.8
通讯作者：
Ueno, N. T.
中科院分区：
文献类型：
--
作者：
Brewer, T. M.;Masuda, H.;Ueno, N. T.
背景：一些研究表明，他汀类药物具有降低胆固醇和抗炎的特性，可能具有抗肿瘤作用。他汀类药物对炎性乳腺癌（IBC）的影响从未被研究过。方法：我们回顾了1995-2011年诊断为原发性IBC并在德克萨斯大学MD安德森癌症中心接受治疗的723例患者。他汀类药物使用者被定义为在初始评估时使用他汀类药物。根据Ahern et al的他汀类药物分类（JNCI，2011），按他汀类药物使用和类型（弱亲脂性至亲水性（H-他汀类药物）与亲脂性他汀类药物（L-他汀类药物））比较临床结局。我们使用Kaplan-Meier方法估计中位无进展生存期（PFS）、总生存期（OS）和疾病特异性生存期（DSS），并使用考克斯比例风险回归模型来检验潜在预后因素的统计学意义。结果：在多变量考克斯模型中，与无他汀类药物相比，H-他汀类药物与PFS显着改善相关（风险比= 0.49; 95%置信区间= 0.28-0.84; P
Background: Some studies have suggested that statins, which have cholesterol-lowering and anti-inflammatory properties, may have antitumor effects. Effects of statins on inflammatory breast cancer (IBC) have never been studied.Methods: We reviewed 723 patients diagnosed with primary IBC in 1995-2011 and treated at The University of Texas MD Anderson Cancer Center. Statin users were defined as being on statins at the initial evaluation. Based on Ahern et al's statin classification (JNCI, 2011), clinical outcomes were compared by statin use and type (weakly lipophilic to hydrophilic (H-statin) vs lipophilic statins (L-statin)). We used the Kaplan-Meier method to estimate the median progression-free survival (PFS), overall survival (OS) and disease-specific survival (DSS), and a Cox proportional hazards regression model to test the statistical significance of potential prognostic factors.Results: In the multivariable Cox model, H-statins were associated with significantly improved PFS compared with no statin (hazard ratio = 0.49; 95% confidence interval = 0.28-0.84; P